Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec …
Sangamo shares plunge after Pfizer ends hemophilia A gene …
Dec 30, 2024 · Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% …
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
Dec 31, 2024 · On Monday, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational …
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia …
Dec 31, 2024 · Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped …
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on …
Dec 31, 2024 · After showing that Pfizer (NYSE:PFE) has halted its cooperation to develop giroctocogene fitelparvovec, an experimental gene therapy for hemophilia A in adults, …
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
Dec 31, 2024 · Shares of Sangamo fell as much as 56% when markets opened on Tuesday in New York, their biggest drop since Nov. 11, 2008. That plunge was tied to disappointing …
Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of ...
New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an …
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug (2)
Dec 31, 2024 · Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A.
Sangamo Therapeutics to Regain Full Rights to ... - Business Wire
Dec 30, 2024 · Pfizer has indicated to Sangamo that this termination reflects its decision not to proceed with the Biologics License Application (BLA) and Marketing Authorisation Application …
Pfizer drops hemophilia gene therapy, imperiling partner Sangamo …
Dec 30, 2024 · Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future.